Panelists at the 2026 TIME100 Health Leadership Forum discussed advancements and challenges in longevity research, underscoring a significant lag in understanding female physiology within medical science.
Neuroscientist Jennifer Garrison noted that research often overlooks the specificities of female bodies, which she argued is a critical oversight. "When we miss female physiology, we’ve essentially left out half of the picture," Garrison stated. She pointed out that while female bodies often exhibit a greater capacity for fighting viruses, the underlying reasons remain poorly understood. This knowledge gap, she explained, hinders the development of tailored medical treatments for all individuals.
Garrison characterized the current state of understanding these physiological differences as being "generations behind," rather than just years or decades. She emphasized that while the medical field is working to catch up, it will be a lengthy process.
Jack Jia, founder and CEO of Musely, a telehealth platform focused on personalized prescription care, shared how his wife's challenges in finding effective treatments for melasma inspired him to expand the platform's scope beyond skincare. Jia observed that the current healthcare system is primarily designed for acute illness rather than addressing broader wellness or cosmetic conditions, which he considers a universal concern.
Navigating the Longevity Landscape
The discussion also touched upon the surge in longevity testing and interventions. Garrison advised caution, stating that while evidence-based tests can be beneficial, the longevity space is susceptible to questionable claims and pseudoscience. "For women, the amount of information and marketing that comes at us these days is crazy," she said, noting the difficulty consumers face in distinguishing credible science from marketing hype.
Echoing concerns about the unchecked enthusiasm in the longevity field, David Sinclair, a prominent researcher in aging, expressed worry about the increasing acceptance of unproven methods, such as peptide injections and experimental drug use. He acknowledged that while individuals have the right to explore options with their doctors, particularly when facing serious conditions with no other recourse, the pendulum may have swung too far from previous regulatory strictness that he felt was overly prohibitive.